Post by
Breakthorough1 on Jul 27, 2023 1:45pm
January 13 2022
"We believe this study should help affirm and extend our understanding of the clinical benefit previously seen in r/r DLBCL patients in the SPiReL trial and may support the use of PD-L1 as a biomarker for MVP-S in combination with KEYTRUDA. Importantly, this is an open-label study, so we expect to review early data in the summer 2022."